Poolbeg Pharma files patent for POLB 001 to be used in cancer treatments

Poolbeg Pharma, a biopharmaceutical company that specialises in infectious diseases, has filed a patent for one of its treatments to be used in cancer treatments.

The treatment, called POLB 001, was developed to address severe influenza, but it has been found to have the potential to address life-threatening side effects in cancer treatment as well.

The London-based Irish company announced that while investigating the role of cytokine release syndrome (CRS) in severe influenza, it discovered data specific to the overt immune response in CAR T cell patients that suggest POLB 001 as a potential treatment.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. POLB 001 has the potential to dampen the pro-inflammatory cytokine release syndrome affecting patients receiving CAR T cell therapies

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Poolbeg Pharma

More articles like this

AI-powered drug discovery is changing the future of medicine

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

The Medicine of Tomorrow

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for